BRAF Mutations in AML: Rare, Biologically Distinct, and Linked to Poor Outcomes
BRAF mutations occur in about 1% of AML and are usually non-V600 variants enriched in myelodysplasia-related disease. This cohort study found poor survival and suggested that current therapies, including venetoclax-based regimens, remain inadequate.
